Innovation is at the core of how we develop breakthrough new products for patients and consumers and Johnson & Johnson Innovation was established to seek out and establish collaborations wherever we find the most promising science.
In October, we expanded our global innovation footprint when Johnson & Johnson Innovation announced the opening of the Asia Pacific Innovation Center. Located in Shanghai with satellites in Singapore, Australia and Japan, the Asia Pacific Innovation Center extends the network of Innovation Centers in life sciences hotspots around the globe. With local science and technology experts and deal-making capabilities, the Center will identify and develop promising early-stage opportunities across the Company’s three areas of focus: Pharmaceuticals, Medical Devices and Consumer healthcare products.
“With the launch the Asia Pacific Innovation Center we are building on the momentum of our Centers in London, California and Boston. Our goal is to collaborate with the best minds in the region to advance new technologies and deliver transformative solutions for the people of China and Asia Pacific at large, and throughout the world,” said Paul Stoffels, MD., Johnson & Johnson Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals.
The Innovation Centers have established well over than 100 collaborations, including eight in the Asia Pacific region in areas such as autoimmune disease, pain relief, oncology and skincare.
“There is an explosion of growth in the Asia Pacific region, and China in particular, as well as significant medical needs. The Asia Pacific Innovation Center builds on a track record of collaboration in the region and will advance the most promising science. It will play a key role in sourcing early stage science in the region for the development of new medicines, medical devices, and consumer products,” said Dong Wu, Head of the Johnson & Johnson Innovation, Asia Pacific.
Johnson & Johnson Innovation is working with key stakeholders in the region including the government, industry and academic partners to accelerate innovation around the world. Through the Innovation Center, regionally-based entrepreneurs and scientists in Asia Pacific have one-stop access to customized support for promising early-stage ideas and technologies including funding, early and commercial expertise.
“The Johnson & Johnson Family of Companies has a long standing presence in China extending back almost 30 years. Our on the ground presence across the region allows us to work side by side with our partners with speed, agility, and insight to translate innovations into new products,” said Jesse Wu, Chairman, Johnson & Johnson China. “The Asia Pacific Innovation Center supports our larger goal to address China’s specific healthcare needs, invest in local capabilities, and increase our external collaborations.”
The Asia Pacific Innovation Center is part of Johnson & Johnson Innovation, a division of Johnson & Johnson (China) Investment Ltd. For more information, please visit www.jnjinnovation.com.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This article contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995, including regarding business strategy and product development. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, challenges and uncertainties inherent in product development and the potential that the expected strategic benefits and opportunities from any external collaboration may not be realized. The readeris cautioned not to rely on these forward-looking statements and should review the Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including in Exhibit 99 thereto, for a further list and description of these risks, uncertainties and other factors. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments